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Purple acid phosphatases aremetal-containing hydrolases.While their precise biological role(s) is unknown, themammalian enzyme
has been linked in a variety of biological circumstances (e.g., osteoporosis) with increased bone resorption. Inhibition of the human
enzyme is a possible strategy for the treatment of bone-resorptive diseases such as osteoporosis. Previously, we determined the crystal
structure of pig purple acid phosphatase to 1.55Aandwe showed that it is a goodmodel for the human enzyme.Here, a study of the pH
dependence of its kinetic parameters showed that the pig enzyme is most efficient at pH values similar to those encountered in the
osteoclast resorptive space. Based on the observation that phosphotyrosine-containing peptides are good substrates for pig purple acid
phosphatase, peptides containing a range of phosphotyrosine mimetics were synthesized. Kinetic analysis showed that they act as
potent inhibitors of mammalian and plant purple acid phosphatases, with the best inhibitors exhibiting low micromolar inhibition
constants at pH 3–5. These compounds are thus the most potent organic inhibitors yet reported for the purple acid phosphatases.
 2004 Published by Elsevier Inc.
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F2Pmp, phosphono(difluoromethyl)phenylalanine; OMT, 4
0-O-(2-mal-Purple acid phosphatases are a group of nonspecific
phosphomonoesterases, members of which have been
characterized from animal, plant, and fungal sources (for
a recent review seeKlabunde andKrebs [1]). An extensive
sequence database search has indicated that purple acid
phosphatases also occur in a limited number of bacterial
organisms (e.g., some cyano- and mycobacteria) [2].
Purple acid phosphatases contain a binuclear FeIII–MeII
center in the active site (where MeII@FeII, ZnII or MnII)
and are distinguished from other acid phosphatases by
their characteristic purple color in concentrated solution,
due to the presence of a tyrosine!FeIII charge transfer
transition. The animal enzymes are also distinguished
from lysosomal and prostatic acid phosphatases by their
resistance to inhibition by L(+)tartrate and are commonly
referred to as ‘‘tartrate-resistant acid phosphatases’’* Corresponding author. Fax: +11-61-7-3365-4699.
E-mail address: susan.hamilton@mailbox.uq.edu.au (S. Hamilton).
0003-9861/$ - see front matter  2004 Published by Elsevier Inc.
doi:10.1016/j.abb.2004.01.008(TRAPs). Purple acid phosphatase activity, the most
commonly used histochemical marker for osteoclasts, is
expressed at high levels by these cells [3]. The enzyme is
secreted into the resorptive space and there is evidence
that it is required for normal bone resorption. Serum
levels are elevated in patients with metabolic bone dis-
eases such as osteoporosis and cancers with bone metas-
tases [4]. A transgenic mouse in which the enzyme is
overexpressed [5] exhibits increased bone turnover and
thus resorption (osteoporosis), while the transgenic
mouse knock-out [6] exhibits the opposite phenotype
(osteopetrosis). Additionally, in an in vitro bone resorp-
tion assay molybdate, an inhibitor of PAP,1 and aonyl)-L-tyrosine; PAP, purple acid phosphatase; Pmp, phosphonom-
ethylphenylalanine; PTyr, phosphotyrosine; RKB PAP, red kidney
bean purple acid phosphatase; SP PAP, sweet potato purple acid
phosphatase.
Scheme 1.
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been speculated that purple acid phosphatase participates
in bone resorption either by dephosphorylation of bone
matrix proteins such as osteopontin [8] or, since purple
acid phosphatase is a redox-active di-iron protein, by pro-
ducing free oxygen radicals using Fenton chemistry [9].
Despite the fact that purple acid phosphatase is a
logical target for drugs suitable for the treatment of
bone-resorptive diseases, little attention has been given
to the development of specific inhibitors for this en-
zyme. The synthesis of a series of naphthalenemethyl-
phosphonic acid derivatives has been reported, one of
which, bis-benzoyl-1-naphthylmethylphosphonic acid,
exhibited an IC50 of 1.4 lM. Phosphonates contain a
stable phosphorus carbon bond in place of the hydro-
lyzable carbon oxygen phosphate ester bond. Such
compounds, while they may be dead end inhibitors of
the enzyme, do not exhibit the desired level of specificity
for an effective drug and may also be toxic. We have
therefore examined alternative strategies for the devel-
opment of specific inhibitors of the mammalian purple
acid phosphatases, based on our knowledge of the
specificity of the enzyme as a phosphotyrosyl protein
phosphatase [10]. We have previously shown that
phosphotyrosine (PTyr) and the PTyr-containing pep-
tide Fmoc-EEY(P)AA are excellent substrates for
mammalian purple acid phosphatases, especially in the
low pH range typical of the osteoclastic space (2.5–3)
[10,11]. We now report (i) an analysis of the pH de-
pendence of the kinetic parameters for pig purple acid
phosphatase, (ii) the results of extended substrate
specificity studies on this enzyme using phosphopep-
tides, and (iii) the development of inhibitors based on
one of the best substrates, Fmoc-EY(P)A (Scheme 1A).
Four PTyr analogues phosphonomethylphenylala-
nine (Pmp), phosphono(difluoromethyl)phenylalanine
(F2Pmp), 4
0-O-(2-malonyl)-L-tyrosine (OMT), and 40-O-
(2-fluoromalonyl)-L-tyrosine (FOMT) have been incor-
porated into the peptide in place of PTyr (Scheme 1B).
Additional modifications are the substitution of the
C-terminal alanine by leucine, the conversion of the C-
terminal carboxy group by an amide, and various
substitutions in the PTyr moiety (Scheme 1C). Inhibi-
tion by the peptides has been examined using native
pig purple acid phosphatase and the recombinant hu-
man and mouse enzymes [11], as well as two plant
purple acid phosphatases, one from red kidney bean
[12] and one from sweet potato [13]. Additionally, the
inhibitory effect of some of these peptides was deter-
mined for metal ion derivatives of pig purple acid
phosphatase. In the absence of crystallographic data
for the enzyme–inhibitor complex, computational
docking of the inhibitor Fmoc-E(F2Pmp)A at the ac-
tive site of the pig enzyme has been undertaken to
visualize interactions important for efficient binding of
the antagonist.Materials and methods
Materials and synthesis of peptides
All chemicals, unless otherwise stated, were of ana-
lytical grade. Reagents for peptide synthesis were
obtained from Auspep, except for protected PTyr ana-
logues, which were synthesized as described previously:
Na-Fmoc-(O,O-di-t-butyl)Pmp [14], Na-Fmoc-(O,O-di-
ethyl) F2Pmp [15], Na-Fmoc-OMT-O,O-(tert-butyl)2
[16], and Na-Fmoc-FOMT-O,O-(tert-butyl)2 [17]. PTyr-
containing peptides were synthesized as described
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peptides of the general formula Fmoc-EXA, where X
represents the PTyr mimetic, using manual solid phase
peptide synthesis as described previously [10]. An ex-
ception was the synthesis of the F2Pmp compound
where deprotection was carried out as described by
Otaka et al. [18]. Peptides were purified by reverse phase
HPLC and mass spectra were recorded as described
previously [10].
Protein purification and enzyme kinetics
Purple acid phosphatases from pig allantoic fluid [19],
red kidney bean [12], and sweet potato [13] and re-
combinant human and mouse from baculovirus-infected
insect cells [11] were prepared as described previously.
All enzyme preparations were at least 95% pure, as
judged by SDS–PAGE analysis and specific activity. The
mammalian enzymes were reduced to their fully active
forms by incubation of stock solutions (2mg/ml) in
0.1M acetate buffer, pH 4.90, with 58mM ferrous am-
monium sulfate and 140mM b-mercaptoethanol [20].
Excess reducing agent was diluted 1000-fold upon
addition of the enzyme to the steady state rate assays.
Metal ion replacements for pig purple acid phosphatase
were carried out according to the method of Beck et al.
[20]. Kinetics of hydrolysis of phosphopeptides and de-
termination of the molar concentration of pig purple
acid phosphatase used for the calculation of kcat were
performed as described previously [10]. The pH depen-
dence of the kinetic parameters for FeIII–FeII pig purple
acid phosphatase was determined in 0.1M glycine buffer
(pH 2.0–3.5), 0.1M acetate buffer (pH 3.5–6.0), and
0.1M Mes buffer (pH 6.0–7.0), using varying concen-
trations of p-NPP or L-PTyr. The kinetic data were
analyzed using the rapid equilibrium diprotic model
[21]. Kinetics of inhibition at pH 3.30 and 4.90 were
analyzed using L-PTyr as substrate [10]. For each
inhibitor, initial rates, monitored at 280 nm, were
determined using a minimum of three inhibitor
concentrations in the range 1–100 lM depending on the
Ki, and for each inhibitor concentration at a range of
substrate concentrations (0.1–10mM) depending on the
apparent Km. Kinetic constants were obtained by non-
linear fit to the Michaelis–Menten equation with com-
petitive inhibition, using DNRPEASY [22].
Modelling strategy
Protons were added to the 1.55A resolution crystal
structure of the pig enzyme (1UTE in the protein data
bank [23]) using BIOPOLYMER, a module of
INSIGHT 2000.1 (Accelrys). For this process, it was
assumed that the protein was at pH 3.5. Three-dimen-
sional models of the inhibitors were constructed using
SKETCHER in INSIGHT 2000.1 and then were energyminimized. The docking of the inhibitors to the protein
was performed using GOLD and followed the standard
protocol as described by Jones et al. [24].Results and discussion
Dependence of kinetics parameters of FeIII–FeII pig
purple acid phosphatase on pH
The pH dependence of the enzyme-catalyzed hydro-
lysis of pNPP and L-PTyr is shown in Fig. 1. The kinetic
parameters and approximate pKa values obtained by
fitting the data using the diprotic model are summarized
in Table 1. Consistent with previous reports for the pig
and red kidney bean enzymes [25], kcat exhibits a maxi-
mum at pH 5.0 for both substrates (Figs. 1A and C).
In contrast, catalytic efficiency (kcat=Km) reaches its op-
timum in the range between pH 3 and 3.5, the pH range
typically found in the osteoclastic resorptive space. The
lower pH optimum for kcat=Km results from the decrease
in Km across the entire pH range under investigation. It
should be emphasized, however, that the pKa values in
Table 1 are approximate, especially in the low pH range
where data are limited.
Interpretation of the pH dependencies is complex
because of the ionizable nature of the substrate and be-
cause the pKa values are not sufficiently well separated to
allow precise determination. However, some tentative
conclusions may be drawn. The protonation equilibria
pKes1 and pKes2 correspond to residues in the enzyme–
substrate complex, which control catalysis [21]. The pKa
of4 (pKes1) may correspond to the ionization of a water
molecule bound to FeIII. The pKa of water coordinated
to ferric ion in model complexes is 3 [26]. The assign-
ment is consistent with spectroscopic studies of the in-
teraction of phosphates with the bovine and pig enzymes
[25,27–30], which revealed an ionization occurring in the
pH range 3.9–4.8. The conjugate base, a coordinated
hydroxyl group, is a potential candidate for the attacking
nucleophile in hydrolysis [25,29–31]. The pKes2 value of
6 may correspond to a residue in the active site acting
as a general acid to protonate the leaving group on hy-
drolysis. Residues previously identified as candidates,
based on the crystal structures of the pig and red kidney
bean enzymes, are the conserved His92 and His195 (pig
enzyme numbering), which are within hydrogen bonding
distance of bound phosphate [23,32].
The equilibrium constants pKe1 and pKe2 correspond
to residues in the free enzyme or the substrate, which
control substrate binding and/or catalysis [21]. The low
pKe1 of 2 may reflect the deprotonation of a water
molecule bridging the metal ions in the active site. The
presence of a bridging l-hydroxo group in the active
purple acid phosphatases from pig, bovine, and red
kidney bean is supported by saturation magnetization
Fig. 1. Kinetic parameters (kcat and kcat=Km) as a function of pH for Fe
III–FeII pig purple acid phosphatase using pNPP (A and B, respectively) and
PTyr (C and D, respectively) as substrates. The data were quantitatively analyzed using equations derived from the diprotic model [21].
Table 1
Kinetic parametersa determined for FeIII–FeII pig purple acid phosphatase using pNPP and PTyr as substrates
Substrate kcat (s1) Ks (mM) pKe1 pKe2 pKes1 pKes2
pNPP 431 1.23 2.28 4.77 4.15 6.11
PTyr 256 1.03 1.83 4.09 3.85 5.68
aKinetic data (kcat, Km, and kcat=Km) measured at pH values ranging from 2 to 7 were analyzed using the diprotic model [21], resulting in estimates
for the protonation equilibria for free enzyme (pKe1 and pKe2) and the enzyme–substrate complex (pKes1 and pKes2). KS, the constant describing the
equilibrium between free enzyme and the ES complex, is assumed to be independent of the protonation state of the enzyme.
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[33,34]. A role as the attacking nucleophile has been
attributed to this bridging group as an alternative to the
hydroxo group coordinated to ferric ion [35–38]. The
pKa of 2 could alternatively be due to the first ioni-
zation of the substrate, although we would expect the
value to be lower—the first acid dissociation of phenyl
phosphate is reported to be 0.3 [25].Hydrolysis of phosphopeptide substrates
Kinetic data for the hydrolysis of a range of phos-
phopeptides by pig purple acid phosphatase are given in
Table 2. As noted previously [10], inclusion of the Fmoc
group at the N-terminus led to a significant decrease
in Km at pH 2.5 and 4.9, suggesting the presence of a
hydrophobic pocket in the vicinity of the active site.
Table 2
Hydrolysis of phosphopeptides by pig purple acid phosphatasea
Substrate kcat (s1), Km (lM)
pH 2.50 pH 4.90
EEY(P)AA 65 5, 140 10 79 1, 310 10
Fmoc-EEY(P)AA 35 2, 6 1 120 5, 75 5
Fmoc-EY(P)A 25 0.5, 8 0.5 31 0.5, 48 2
Fmoc-AAY(P)AA ND 100 20, 120 20
Fmoc-KKY(P)AA ND 170 40, 950 200
aMeasured at 25 C in 0.1M acetate buffer, pH 4.90, or 0.1M
glycine buffer, pH 2.50. ND, not determined.
Table 4
Inhibition of pig PAP by selected peptides
Inhibitor pH 3.3 pH 4.9
aKiðcÞ (lM) KiðucÞ (lM) KiðcÞ (lM) KiðucÞ (lM)
FmocE(OMT)A 6 1 — 38 1 —
FmocE(OMT)
A-amide
24 3 — 182 16 —
FmocE(OMT)L 8 1 190 9 49 4 —
FmocE(OMT)
L-amide
5 1 — 18 1 —
aKiðcÞ and KiðucÞ are the competitive and uncompetitive inhibition
constants, respectively.
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Ala caused only negligible change in Km, whereas re-
placement by Lys led to an increase in Km of 12-fold at
pH 4.90. For all peptides, Km values were lower and
kcat=Km values were higher at pH 2.50 than 4.90, con-
sistent with the pH dependencies seen for pNPP and
PTyr (Table 1). The lowest Km values for the peptides
Fmoc-EY(P)A and Fmoc-EEY(P)AA were in the low
micromolar range at pH 2.5, suggesting that the pep-
tides provided a good starting point for the synthesis of
substrate analogues containing PTyr mimetics. Since
Fmoc-EY(P)A was almost as good a substrate as Fmoc-
EEY(P)AA and exhibited the same Km within experi-
mental error, it was used as the parent compound for the
synthesis of the inhibitors.
Inhibition of purple acid phosphatases
The substrate analogues based on Fmoc-EY(P)A
(Scheme 1) are all potent inhibitors of Fe–Fe pig purple
acid phosphatase. The Ki values (summarized in Table
3) are lower at pH 3.30 than 4.90 and are in the mi-
cromolar range, comparable with the Km values for the
substrate on which these inhibitors are based (Table 2).
These peptides are thus very effective inhibitors of the
enzymes, comparable at least with the best of the
naphthalenemethylphosphonic acid derivatives [39].
The inhibitory effect of these analogues was also as-
sessed for the recombinant human and mouse purple
acid phosphatases [11], as well as the enzymes isolatedTable 3
Inhibition of PAPs by phosphotyrosyl analogs (aKiðcÞ and KiðucÞ values in lM
Enzyme FmocEY(Pmp)A FmocEY(F2Pmp)A
pH 3.3 pH 4.9 pH 3.3 pH 4.9
KiðcÞ KiðucÞ KiðcÞ KiðucÞ KiðcÞ KiðucÞ KiðcÞ Ki
Human PAP ND ND ND ND 67 — 63 —
Mouse PAP 8 13 50 143 18 — 62 —
Pig PAP 53 — 85 — 14 — 87 —
RKB PAP 77 — 66 — 7 — 29 —
SP PAP 83 — 105 — 23 — 80 —
ND not determined.
aKiðcÞ and KiðucÞ are the competitive and uncompetitive inhibition constafrom red kidney bean [12] and sweet potato [13]. The Ki
values are in the range from 1 to 100 lM. These inhib-
itors are in general more potent at low pH, a desirable
property for their further use in the development of
drugs against bone-resorptive disorders (pH in osteo-
clastic space ranges from 2.5 to 3). Fluorination of the
OMT moiety in the peptide analogue (Scheme 1) leads
to a decrease in the inhibitory effect in all but the sweet
potato enzyme. The effect of the fluorination of the Pmp
moiety displays no clear trend in the inhibition of the
mammalian enzymes, however, both plant purple acid
phosphatases are inhibited more strongly by the fluori-
nated analogue, again suggesting stabilizing interactions
via H-bonding and/or by positively charged residues.
Increasing the hydrophobicity of the tripeptide had
no significant effect on the inhibition of pig purple acid
phosphatase. Starting from Fmoc-E(OMT)A the ala-
nine was replaced by leucine. Virtually no differences in
inhibition were apparent (Table 4). For the Fmoc-
E(OMT)A/L series replacing the C-terminal carboxylate
by an amide group affected the potency of the inhibitors
only mildly. The largest effect on inhibition was achieved
by modifying the tyrosine moiety (Scheme 1C and Table
5). Substitution at the C5 position of the aromatic ring
with carboxy- and acetoxy groups greatly reduces the
binding affinity of the OMT-containing inhibitor (D1–
D3), probably due to steric interactions. However, re-
placing the O-malonyl group by formyl (D4), and thus
preventing the interaction of this OMT inhibitor with)
FmocE(OMT)A FmocE(FOMT)A
pH 3.3 pH 4.9 pH 3.3 pH 4.9
ðucÞ KiðcÞ KiðucÞ KiðcÞ KiðucÞ KiðcÞ KiðucÞ KiðcÞ KiðucÞ
14 — 26 — 36 23 74 —
2.9 — 62 — 55 70 15 —
1.9 — 47 — 12 38 50 —
0.9 6.8 41 — 31 — 15 —
5.8 — 81 — 0.9 — 17 —
nts, respectively.
Table 5
Inhibition of pig PAP by derivatives of FmocE(OMT)L-amide
Inhibitor pH 3.3 pH 4.9
bKiðcÞ (lM) KiðucÞ (lM) KiðcÞ (lM) KiðucÞ (lM)
FmocE(OMT)
L-amide
5 1 — 18 1 —
FmocE(D1)L-amidea 201 12 — 279 3 —
FmocE(D2)L-amidea 112 11 — 146 14 —
FmocE(D3)L-amidea 413 18 — 777 37 —
FmocE(D4)L-amidea 100 1 — 161 2 —
FmocE(D5)L-amidea 6 1 — 38 1 —
FmocE(D6)L-amidea 8 1 190 11 49 4 —
aD1 to D6 refer to the aromatic side chains shown in Scheme 1C.
bKiðcÞ and KiðucÞ are the competitive and uncompetitive inhibition
constants, respectively.
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effect (Table 5). This suggests that bidentate binding of
the substrate analogue is crucial to achieve specific and
strong inhibition. Consistently, the replacement of the
O-malonyl group by malonyl (D5 and D6) displays only
a minor effect, since the slightly shorter side chain may
still be able to bind to both metal ions simultaneously.
Again fluorination leads to an increase in Ki (D6).
The effect of changing the metal centers on inhibition
has also been examined. FeIII–ZnII and FeIII–MnII de-
rivatives of pig purple acid phosphatase (which mimic
the binuclear centers in red kidney bean and sweet po-
tato purple acid phosphatases, respectively [40,41]) were
generated according to published procedures [20,30],
and inhibition data were collected for both the OMT-
and the FOMT-containing tripeptides (Scheme 1) at pH
3.3 and 4.9. The results are summarized in Table 6.
Replacing FeII by ZnII does increase the affinity of pig
purple acid phosphatase for these inhibitors, ap-
proaching the Ki values obtained for the red kidney bean
enzyme (Table 3). The affinity of the FeIII–MnII deriv-
ative of pig purple acid phosphatase for OMT is mod-
erately weaker than that of the native pig enzyme,
resembling that of sweet potato purple acid phospha-
tase. However, for FOMT both an increase in its in-
hibitory potency and the type of inhibition was observed
(uncompetitive and noncompetitive at pH 3.3 and 4.9,Table 6
Inhibition of metal ion derivatives of pig PAP by OMT- and FOMT-contai
Metal content Inhibitor pH 3.3
aKiðcÞ (lM)
FeIII–FeII FmocE(OMT)A 6 0.2
FeIII–ZnII FmocE(OMT)A 2.4 0.2
FeIII–MnII FmocE(OMT)A 10 1.6
FeIII–FeII FmocE(FOMT)A 12 1.6
FeIII–ZnII FmocE(FOMT)A 0.8 0.1
FeIII–MnII FmocE(FOMT)A —
aKiðcÞ and KiðucÞ are the competitive and uncompetitive inhibition constanrespectively). A similar trend has been seen for the sweet
potato enzyme (Table 3), although the type of inhibition
remains competitive. Incorporation of MnII into the
active site of pig purple acid phosphatase may cause
some conformational change that affects the binding
mode of the fluorinated inhibitor. Attempts to crystal-
lize pig purple acid phosphatase in the presence of OMT
and FOMT have not been successful, however, an
analysis by molecular modeling of the structure of the
native pig enzyme reveals factors which may be impor-
tant for the determination of inhibition specificity (vide
infra).
Inhibitor–protein interactions
We have determined the crystal structure of pig
purple acid phosphatase [23] and other groups have
solved the structures of the rat enzyme [42,43]. The
overall structural features of these mammalian enzymes
are very similar, as expected based on the very high
degree of sequence identity (>85%) [1]. Furthermore,
despite low sequence homology the structure of red
kidney bean purple acid phosphatase [32] displays an
active site geometry very similar to those of the mam-
malian enzymes. The seven metal-coordinating amino
acids are invariant and binding of the substrate leads to
the formation of a l-phosphate complex. However,
apart from the binding of the phosphate group the in-
teractions between substrate and protein are still poorly
understood. The following features in the active site of
pig purple acid phosphatase may play an important role
in the interactions between protein and substrate/in-
hibitor. The two Fe atoms lie at the base of a cavity
(Fig. 2) approximately 7A deep. The length of the
cavity, which extends from the NE2 atom of Glu151 to
the CZ atom of Phe 244, is 11.4A. The maximum width
of the cavity (from the CE1 atom of His195 to the OD1
atom of Asp146) is 7A. The side chains of the metal
binding ligands His221, His223, Tyr55, and Asn91 form
a shelf that protrudes outward from the Fe atom base.
The four metal binding atoms of these ligands form the
corners of a rectangle 6.4A by 3.2A. The outer layer of
the active site consists of eight residues, which have theirning peptides
pH 4.9
KiðucÞ (lM) KiðcÞ (lM) KiðucÞ (lM)
— 38 1 —
— 1.6 0.2 —
250 20 77 3 —
38 4 50 2 —
— 16 0.6 —
1.6 0.2 1.5 0.2 1.2 0.1
ts, respectively.
Fig. 2. Proposed interaction of pig purple acid phosphatase and pep-
tide inhibitor. A Connolly surface representation of the active site
region. The negatively charged amino acid residues (Asp and Glu) are
colored red and the positively charged residues (Lys and Arg) are
colored blue. All remaining amino acid residues are colored white. The
metal ions are colored tan for FeIII and red for the redox-active FeII=III
and they can be seen just protruding above the surface. The highest
ranked docking solution of the F2PMP peptide to the enzyme is de-
picted as a stick model and color-coded such that green is for carbon,
red for oxygen, blue for nitrogen, and aquamarine for fluorine. The
groove on the surface is lined with charged amino acids and may be a
region for the development of second generation inhibitors.
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They include residues His92, Phe56, Phe244, Asp246,
Glu194, His195, Gln151, and Asp146. The latter residue
is part of an exposed loop, only present in mammalian
purple acid phosphatases. Proteolytic cleavage within
this loop has been associated with a significant increase
in enzyme activity for rat and human purple acid
phosphatases [37]. Based on site-directed mutagenesis
studies, it has been proposed that the H-bond interac-
tion between Asp146 and the FeII ligand Asn91 is cru-
cial for the regulation of enzyme reactivity [37];
disrupting this interaction completely leads to the
strongest catalytic enhancement. This may also be a
reason for the variation of inhibition by fluorinated Pmp
inhibitors observed for pig and mouse purple acid
phosphatases (Table 3). A narrow groove, approxi-
mately 5A deep (Fig. 2), is connected to the main cavity.
It is bordered by Gln151, Ser150, and Gln152 on one
side and on the other by Glu194, Lys250, and His 251.
Distances across the groove are 5.6A between the NE2
atom of His251 and the NE2 atom of Gln152, 7.0A
between the carbonyl oxygen of Ser150 and the NZ
atom of Lys250, and 6.8A between the NE2 atom of
Gln151 and the OE2 atom of Gln194.
No crystals of enzyme–peptide-inhibitor complexes
have yet been obtained. We have therefore docked theinhibitor Fmoc-E(F2Pmp)A into the active site of the
crystal structure of pig purple acid phosphatase. Fig. 2
shows two views of the highest ranked solution found
with GOLD. The oxygen atoms from the phosphonate
are bound to the iron atoms and complete the octahe-
dral geometry. The aromatic ring of the phosphotyrosyl
side chain fits into the cavity (Fig. 2) and makes van der
Waals contacts with His195, Asn91, Glu151, and
Ser145. In this docking solution, the carboxyl group of
the glutamic acid in the F2Pmp inhibitor forms a hy-
drogen bond with the two peptide amide groups of the
inhibitor. This raises the possibility that the requirement
for glutamic acid at this position may be important for
peptide conformation, rather than binding to the en-
zyme. This suggestion is consistent with the observed
reduction in binding affinity when this glutamate is re-
placed by alanine or lysine (Table 2). The glutamic acid
in the inhibitor imposes a conformation, where the
Fmoc group is able to stack against a hydrophobic
patch on the wall of the cavity, which includes Tyr55,
Phe56, and Phe244. While the different solutions found
using the, GOLD program [24] display considerable
variations in spatial orientations (data not shown), the
positions of the phosphonotyrosyl side chains are in
close agreement, indicating that this part of the sub-
strate analogue undergoes specific interactions with the
protein that support tight binding. Modifications within
this phosphotyrosine moiety lead to a great increase in
the inhibition constant (Table 5). In contrast, for the
remainder of the peptide several conformations are
possible, suggesting less specific interactions between
inhibitor and protein. There are several hydrophobic
surfaces where the Fmoc group could potentially be
located. Parallel studies with the Fmoc-E(OMT)A pep-
tide docked onto the pig enzyme show a distribution of
docking solutions similar to that found for the Fmoc-
E(F2Pmp)A peptide (data not shown). In the top 10
solutions, the OMT group is located in approximately
the same orientation as the F2Pmp moiety and again
there are several alternative locations for the Fmoc
group. Overall there is good evidence to suggest that the
GOLD program has correctly oriented both the OMT
and the F2Pmp groups, whereas the positioning of the
Fmoc group remains speculative. In the X-ray structure
of pig purple acid phosphatase, this groove is filled by
eight ordered water molecules [23], making it a target
region that could be exploited for improving inhibitor
affinity.
Crystals of human purple acid phosphatase have been
produced, but no structural data have been published
[44]. However, human and pig enzymes are 88% iden-
tical with only seven nonconserved differences. A ho-
mology model shows few changes near the active site so
that the pig enzyme appears to be a good model for the
intact human purple acid phosphatase [23]. Further-
more, as mentioned above, a comparison between the
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potato [45] purple acid phosphatases shows that despite
overall low sequence homology, the core structures are
very similar. Apart from variations in metal ion com-
position (FeIII–FeII, FeIII–ZnII, and FeIII–MnII, respec-
tively), there are variable loops in the vicinity of the
active sites, which may contribute to differences in
substrate and inhibitor specificity [23,46]. The inhibition
data presented here show that various plant and mam-
malian purple acid phosphatases bind the tripeptide
inhibitors with affinities similar to the pig enzyme (Table
4). Both plant and mammalian purple acid phosphatases
also have pH-dependent Ki values for all tested inhibi-
tors, with higher binding affinity at lower pH. It is in-
teresting to note that at pH 3.3 the FOMT peptide is a
less effective inhibitor than the OMT peptide for most
purple acid phosphatases (Table 3). The exception is the
Fe- and Mn-containing sweet potato purple acid phos-
phatase, which has a 4- to 5-fold higher affinity for the
FOMT peptide. This inverted behavior may be due, at
least in part, to the different metal ion compositions; the
FeIII–MnII derivative of pig purple acid phosphatase
also appears to be stronger inhibited by FOMT (Table
6). Furthermore, previous work on the inhibition of
PTyr protein phosphatase 1B showed that an FOMT-
containing peptide exhibited a 10-fold higher affinity for
the enzyme than the corresponding OMT peptide [17],
which was attributed in part to an additional hydrogen
bond between the fluorine and a group on the enzyme.
The pKa value for the second ionization of the OMT
malonyl group is affected by fluorine substitution: 3.9
for malonyl vs 2.84 for the fluoro derivative [17]. The
FOMT peptide would therefore carry a larger negative
charge than the OMT peptide, especially at pH 3.3.
Finally, phosphate has been shown to bind to the bi-
nuclear center of the purple acid phosphatases by
bridging the metal ions [23,42,45]. Thus, if the malonyl
group bound similarly it might be anticipated that the
dianion would bind more effectively than the monoan-
ion. That this is indeed the case is supported by the
observation that removal of the malonyl group greatly
reduces the binding affinity of the resulting substrate
analogues (Table 5).
In conclusion, we have identified high-affinity, pep-
tide-based inhibitors of purple acid phosphatases. While
the tripeptide and Fmoc parts of the inhibitors con-
tribute to their overall affinity through moderately
specific, hydrophobic interactions, the modified phos-
photyrosyl moiety is responsible for both tight and
specific binding to the active site. The presented sub-
strate analogues are potent inhibitors for all purple acid
phosphatases and may prove valuable [1] in the devel-
opment of chemotherapeutic agents against osteoporo-
sis and [2] in probing the specificity of purple acid
phosphatase as a phosphotyrosyl protein phosphatase.
Since the physiological substrate(s) and function(s) ofpurple acid phosphatases are unknown, this may pro-
vide insight into the role of these enzymes. Of particular
interest is the observation that these tripeptide-based
inhibitors are most potent at pH values similar to those
measured in the osteoclastic space (3). Further im-
provement of the potency of this group of inhibitors
may be achieved once crystallographic data of purple
acid phosphatases with bound analogues become avail-
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